Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...

Breast cancer classed as HER2-positive – defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease.

Q4 2024 Earnings Call Transcript March 3, 2025 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.11 ...

Martin Huber; President, Chief Executive Officer, Director; Mersana Therapeutics Inc Brian Deschuytner; Chief Financial Officer, Chief Operating Officer, Senior Vice President; Mersana Therapeutics ...

which we define as an IHC score of 70% or more. Focusing specifically on the evaluable patients in this dose range with B7-H4 high triple negative breast cancer, the confirmed ORR was also 23%.

HER2-low status was defined as immunohistochemistry (IHC ... correlated with higher ERBB2 mRNA expression in comparison to HER2-zero tumors, with a mean score of 9.3 vs. 9.1 (p < .001) in WSG-ADAPT ...

Based on the consistent results across tumors with IHC 3+ score, the FDA approval recognizes the HER2 overexpression as IHC 3+ for treatment eligibility with T-DXd as a tumor-agnostic therapy. However ...